Suxamethonium
Suxamethonium is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against acetylcholine receptor subunit alpha.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
180 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | — | — | — | 4 | 7 | 11 |
| Anesthesia | D000758 | — | — | — | — | — | 3 | 5 | 8 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 1 | — | — | 2 | 5 | 8 |
| Neuromuscular blockade | D019148 | — | — | — | 1 | 1 | 3 | 2 | 7 |
| Dyslipidemias | D050171 | — | — | 2 | — | 2 | 1 | 1 | 6 |
| Intratracheal intubation | D007442 | — | — | — | 1 | 1 | 2 | 2 | 6 |
| Intubation | D007440 | — | — | — | — | — | 1 | 4 | 5 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | — | 4 | 1 | 5 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | — | 2 | 3 | 5 |
| Electroconvulsive therapy | D004565 | — | — | — | — | — | 1 | 3 | 4 |
Show 50 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myalgia | D063806 | — | M79.1 | — | 2 | 4 | — | 4 | 8 |
| Prostatic neoplasms | D011471 | — | C61 | — | 2 | 2 | — | 2 | 5 |
| Fasciculation | D005207 | — | R25.3 | — | — | 3 | — | 2 | 5 |
| Hypertriglyceridemia | D015228 | EFO_0004211 | — | 1 | 1 | 1 | — | 1 | 4 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 1 | 2 | — | 2 | 4 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | 2 | 1 | — | 1 | 3 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | — | 1 | — | 2 | 3 |
| Glaucoma | D005901 | EFO_0000516 | H40 | — | — | 1 | — | 2 | 3 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 1 | 1 | — | 1 | 2 |
| Coronary disease | D003327 | — | — | — | — | 2 | — | — | 2 |
Show 24 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 6 | 1 | — | — | 3 | 9 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | 1 | — | — | 1 | 2 |
| Gastric bypass | D015390 | EFO_0005244 | — | — | 1 | — | — | — | 1 |
| Heart valve diseases | D006349 | EFO_0009551 | I08 | — | 1 | — | — | — | 1 |
| Macular edema | D008269 | — | — | — | 1 | — | — | — | 1 |
| Edema | D004487 | — | R60.9 | — | 1 | — | — | — | 1 |
| Exocrine pancreatic insufficiency | D010188 | — | K86.81 | — | 1 | — | — | — | 1 |
| Marijuana abuse | D002189 | EFO_0007191 | F12 | — | 1 | — | — | — | 1 |
| Triple negative breast neoplasms | D064726 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatolenticular degeneration | D006527 | Orphanet_905 | E83.01 | 3 | — | — | — | — | 3 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 2 | — | — | — | — | 2 |
| Diet therapy | D004035 | — | — | 1 | — | — | — | 1 | 2 |
| Child development | D002657 | — | — | 1 | — | — | — | 1 | 2 |
| Food diet and nutrition | D000066888 | — | — | 1 | — | — | — | — | 1 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | — | — | — | 3 | 3 |
| Heart disease risk factors | D000082742 | — | — | — | — | — | — | 3 | 3 |
| Patient satisfaction | D017060 | — | — | — | — | — | — | 2 | 2 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 2 | 2 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | — | — | — | — | 2 | 2 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | — | — | — | — | 1 | 1 |
| Disease | D004194 | EFO_0000408 | R69 | — | — | — | — | 1 | 1 |
| Pharyngitis | D010612 | — | R07.0 | — | — | — | — | 1 | 1 |
| Body weight | D001835 | EFO_0004338 | — | — | — | — | — | 1 | 1 |
| Body weight changes | D001836 | — | — | — | — | — | — | 1 | 1 |
Show 51 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Suxamethonium |
| INN | suxamethonium chloride |
| Description | Succinylcholine is a quaternary ammonium ion that is the bis-choline ester of succinic acid. It has a role as a neuromuscular agent, a muscle relaxant and a drug allergen. It is a quaternary ammonium ion and a succinate ester. |
| Classification | Small molecule |
| Drug class | quaternary ammonium derivatives; quaternary ammonium derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C |
Identifiers
| PDB | — |
| CAS-ID | 306-40-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL703 |
| ChEBI ID | 45652 |
| PubChem CID | 5314 |
| DrugBank | DB00202 |
| UNII ID | J2R869A8YF (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,273 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use